FilingReader Intelligence
Simcere's Enzeshu® receives marketing approval in China
July 3, 2025 at 05:02 PM UTC•By FilingReader AI
Simcere Pharmaceutical Group (HKEX:2096) announced that ENZESHU® (Suvemcitug for injection), a category 1 biological new drug, received marketing approval in China on June 30th from the National Medical Products Administration (NMPA). ENZESHU® is indicated for recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in adults, used in combination with specific therapies after platinum resistance.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:2096•Hong Kong Exchange
News Alerts
Get instant email alerts when Simcere Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime